Original language | English |
---|---|
Pages (from-to) | 614-617 |
Number of pages | 4 |
Journal | European Heart Journal |
Volume | 41 |
Issue number | 5 |
DOIs | |
State | Published - 1 Feb 2020 |
Continuedmisuse of orphan drug legislation: A life-threatening risk for mexiletine
Pieter G. Postema*, Peter J. Schwartz, Elena Arbelo, Wilbert J. Bannenberg, Elijah R. Behr, Bernard Belhassen, Josep Brugada, Pedro Brugada, A. John Camm, Ruben Casado-Arroyo, Ellent Hoen, Carla E.M. Hollak, Stefan Kaab, Pier D. Lambiase, Antoine Leenhardt, Silvia G. Priori, Vincent Probst, Bas C. Stunnenberg, Jacob Tfelt-Hansen, Baziel G.M. Van Engelen
*Corresponding author for this work
- Academic Medical Centre
- IRCCS Istituto Auxologico Italiano - Milano
- University of Barcelona
- Centro de Investigación Biomédica en Red
- Pharmaceutical Accountability Foundation
- University of London
- Hadassah University Medical Centre
- Vrije Universiteit Brussel
- St. George's University of London
- Université libre de Bruxelles
- Medicines Law and Policy
- University of Groningen
- Ludwig Maximilian University of Munich
- German Centre for Cardiovascular Research
- Barts Health NHS Trust
- Université Paris Cité
- University of Pavia
- Service de Cardiologie
- Radboud University Nijmegen
- University of Copenhagen
- Hannover Medical School
Research output: Contribution to journal › Review article › peer-review
20
Scopus
citations